From "The Pharma Letter"
Mr Gozlan said: “Nathan, Geert and I are delighted to join the company at this time with such a compelling technology targeting large unmet medical needs. The results from the oxymorphone patch trial, announced in October, indicate the company is well on the
way to finalising development and commercialisation of this novel and valuable product. We look forward to continuing to revamp Phosphagenics and help drive commercialization and also look forward to potential additions to the board and senior executive team in the future.”
More at:
http://www.thepharmaletter.com/article/phosphagenics-appoints-three-new-non-executive-directors
poh has a new board, page-61
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $20.06K | 10.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 32398999 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 46150696 | 25 |
View Market Depth
| Last trade - 13.15pm 13/09/2024 (20 minute delay) ? |
| AVE (ASX) Chart |